Home   /  Find a Trial  /  See All Trials HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

see All Trials

Sort by zip code:  




4 trials contain the search term(s): "irinotecan"

Camptosar and Veliparib for Advanced Breast Cancer

A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors (NCT00576654)


Irinotecan hydrochloride (Camptosar) is a chemotherapy drug that can kill cancer cells by damaging their DNA. Veliparib is a type of targeted therapy called a PARP inhibitor. It blocks the PARP protein from repairing damaged DNA in cancer cells. Researchers think combining a PARP inhibitor with Camptosar will make it more effective. This study is investigating the side effects and best dose of veliparib when it is given along with Camptosar to treat patients with advanced breast cancer.
This is a Phase I trial

Etirinotecan Pegol For Brain Metastases From Breast (or Lung) Cancer

A Phase II Study of Etirinotecan Pegol (NKTR 102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC) (NCT02312622)


Pegylated irinotecan NKTR-102 is a new version of the chemotherapy drug irinotecan (Camptosar). It was designed to be more effective and have fewer side effects than the original version. This study is investigating how well pegylated irinotecan NKTR-102 works in patients with breast (or lung) cancer that has spread to the brain and has not responded to other treatment.
This is a Phase II trial

IMMU-132 for Metastatic Breast Cancer

A Phase I Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer (NCT01631552)


New treatments are needed for metastatic breast cancer. IMMU-132 is an experimental drug that combines a monoclonal antibody that binds to cancer cells with a chemotherapy agent. The chemotherapy agent is an active form of Irinotecan (Camptosar®), which is used to treat metastatic breast cancer and other types of cancers. Laboratory studies suggest that IMMU-132 maybe an effective way of delivering chemotherapy directly to breast cancer cells. (It is also being studied in 12 other types of cancers.) The purpose of this study is to test the safety of IMMU-132 at different dose levels.
This is a Phase I-II trial

Sacituzumab Govitecan for Previously Treated Advanced Triple Negative Breast Cancer

Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer (ASCENT) (NCT02574455)


To take part in this study, you must have been diagnosed with triple negative (ER-/PR-/HER2-) advanced (some stage III) or metastatic (stage IV) breast cancer that stopped responding to at least two different chemotherapy regimens. This study is comparing the effects (good and bad) of a new targeted therapy for advanced triple negative breast cancer to a standard of care treatment selected by the patient's oncologist. The targeted therapy is sacituzumab govitecan (IMMU-132). It uses an antibody that can target the protein TROP-2 to help bring the chemotherapy irinotecan (Camptosar®) directly into the cancer cells.
This is a Phase III trial